- Details
- Description
-
Packaging Size1Vail/Bottle
-
Strength100mg(10ml)
-
Compositonsintilimab
-
Treatmentlymphoma,lung cancer,Hepatocellular Carcinoma
-
FormInjection
-
BrandTYVYT®
-
Quantity Unit100mg(10ml)*1/Bottle
-
ManufacturerInnovent Bio,China
TYVYT® (sintilimab injection) is a fully human IgG4 monoclonal antibody, which specifically binds to PD-1 expressed on the surface of T cells to block the interaction between PD-L1 and PD-1, thereby reinvigorating exhausted T cell to gain effector function to kill tumor cells.
In December 2018, TYVYT® (sintilimab injection) was first approved by the China NMPA for the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy.
In February 2021, TYVYT® (sintilimab injection) was approved by the China NMPA in combination with pemetrexed and platinum chemotherapy as first-line therapy for the treatment of nonsquamous non-small cell lung cancer.
In June 2021, TYVYT® (sintilimab injection) was approved by the China NMPA in combination with gemcitabine and platinum chemotherapy as the first-line therapy for the treatment of squamous non-small cell lung cancer.
In June 2021, TYVYT® (sintilimab injection) was approved by the China NMPA in combination with BYVASDA® (bevacizumab biosimilar) as the first-line therapy for the treatment of Hepatocellular Carcinoma.
In December 2021, TYVYT® (sintilimab injection) was the only PD-1 inhibitor in China with four major indications (1L nsq NSCLC, 1L sq NSCLC, 1L HCC and cHL) approved and included in China’s NRDL.
In June 2022，TYVYT️® (sintilimab injection) was approved by the NMPA for the fifth indication in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
In June 2022, TYVYT® (sintilimab injection) was approved by the NMPA for the sixth indication in combination with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
